<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147805">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01666587</url>
  </required_header>
  <id_info>
    <org_study_id>IRAPC</org_study_id>
    <secondary_id>DBD0300</secondary_id>
    <nct_id>NCT01666587</nct_id>
  </id_info>
  <brief_title>Ischemia Reperfusion: Prostaglandins and Antioxidants</brief_title>
  <official_title>The Role of Prostaglandin and Anti-oxidant Availability on Recovery From Forearm Ischemia-reperfusion Injury in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Essex</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Essex</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are two-fold. The first purpose is to determine the effect of
      taking vitamins on the recovery of an artery (blood vessel) following an induced temporary
      injury. The second purpose is to determine whether a specific vasodilator is less abundant
      after the injury and whether this contributes to increased constriction or after the injury.
      Finally, does vitamin consumption have an effect on the recovery from the injury if one of
      the substances in the blood that causes vessels to enlarge (dilate) is stopped?
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2014</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Change in flow mediated dilation</measure>
    <time_frame>Change from baseline at 15 minutes after ischemia-reperfusion injury</time_frame>
    <safety_issue>No</safety_issue>
    <description>Flow mediated dilation is a measure of vascular function and is measured as the outcome before and after an injury to the inner lining of the artery.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in low flow mediated constriction</measure>
    <time_frame>Change from baseline at 15 minutes after ischemia-reperfusion injury</time_frame>
    <safety_issue>No</safety_issue>
    <description>low flow mediated constriction is a measure of vascular function and is measured to establish the impact of a vascular injury</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Ischemic Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control trial to determine the impact of the ischemic injury on vascular function without intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antioxidant load</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trial to determine the impact of an antioxidant load before the ischemic injury on vascular function recovery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prostaglandin inhibition</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trial to determine the impact of a non-selective prostaglandin inhibitor before the ischemic injury on vascular function recovery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Combined</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Trial to determine the impact of an antioxidant load and prostaglandin inhibitor before the ischemic injury on vascular function recovery</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Antioxidant</intervention_name>
    <arm_group_label>Antioxidant load</arm_group_label>
    <arm_group_label>Combined</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prostaglandin inhibitor (Ibuprophen)</intervention_name>
    <arm_group_label>Prostaglandin inhibition</arm_group_label>
    <arm_group_label>Combined</arm_group_label>
    <other_name>ibuprofen</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males

          -  Healthy females

        Exclusion Criteria:

          -  Smokers

          -  Cardiovascular disease

          -  Peripheral vascular disease

          -  Neurological deficits

          -  Diabetes Type I or II

          -  Pregnant women

          -  Adverse reactions to Ibuprofen
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Rakobowchuk, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Essex</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Essex</name>
      <address>
        <city>Colchester</city>
        <state>Essex</state>
        <zip>CO4 3SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Rakobowchuk, PhD</last_name>
      <phone>44(0)1206873332</phone>
      <email>merako@essex.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Mark Rakobowchuk, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 15, 2012</lastchanged_date>
  <firstreceived_date>August 9, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Essex</investigator_affiliation>
    <investigator_full_name>Mark Rakobowchuk</investigator_full_name>
    <investigator_title>Principle Investigator</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antioxidants</mesh_term>
    <mesh_term>Prostaglandin Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
